(NVS) Novartis - Ratings and Ratios
Cardiovascular,Oncology,Immunology,Neuroscience,Hematology
NVS EPS (Earnings per Share)
NVS Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.9% |
| Value at Risk 5%th | 30.2% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 12.07 |
| Character | |
|---|---|
| Hurst Exponent | 0.764 |
| Beta | 0.569 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.95% |
| Mean DD | 4.72% |
Description: NVS Novartis September 24, 2025
Novartis AG (NYSE: NVS) is a Swiss-based, globally integrated pharmaceutical company that researches, develops, manufactures, distributes, markets and sells prescription medicines across a broad therapeutic spectrum.
Key product highlights include Entresto for heart-failure with reduced ejection fraction, Cosentyx for psoriasis and related inflammatory diseases, Kisqali (CDK4/6 inhibitor) for breast cancer, Promacta/Revolade for immune-mediated thrombocytopenia, the Tafinlar + Mekinist combo for targeted oncology, and Jakavi for myelofibrosis and related disorders. Additional assets span Tasigna for chronic myeloid leukemia, Xolair for allergic asthma, Ilaris for autoinflammatory conditions, Pluvicto for metastatic castration-resistant prostate cancer, Sandostatin formulations for neuroendocrine tumors, Zolgensma for spinal muscular atrophy, Lucentis for retinal disease, Leqvio (inclisiran) for LDL-cholesterol reduction, Lutathera for neuroendocrine tumors, Scemblix and Fabhalta among others.
The company’s therapeutic focus is concentrated in cardiovascular-renal-metabolic, immunology, neuroscience, oncology and hematology, reflecting both the highest unmet-need areas and the segments with the strongest pipeline growth potential.
Novartis maintains a strategic partnership with Alnylam Pharmaceuticals to co-develop, manufacture and commercialize Leqvio, leveraging RNA-interference technology to expand its lipid-lowering franchise.
Financially, Novartis reported FY 2023 revenue of $51.6 billion, with an operating margin of 23 % and R&D expenditure of $9.6 billion, underscoring its commitment to pipeline renewal. The dividend yield hovered around 3.5 % and the company returned $8.0 billion to shareholders via buybacks and dividends, indicating a mature cash-generation profile.
Sector-level drivers that will likely shape Novartis’ outlook include an aging global population driving demand for chronic-disease therapies, continued pricing pressure in the United States, and accelerating adoption of advanced modalities such as gene-therapy and RNA-based medicines, which are reshaping competitive dynamics.
For a deeper quantitative assessment of Novartis’ valuation metrics, you may find the ValueRay platform useful.
NVS Stock Overview
| Market Cap in USD | 242,740m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1991-11-18 |
| Return 12m vs S&P 500 | 8.26% |
| Analyst Rating | 2.85 of 5 |
NVS Dividends
| Dividend Yield | 3.14% |
| Yield on Cost 5y | 6.04% |
| Yield CAGR 5y | 5.30% |
| Payout Consistency | 96.4% |
| Payout Ratio | 44.7% |
NVS Growth Ratios
| CAGR | 22.15% |
| CAGR/Max DD Calmar Ratio | 1.11 |
| CAGR/Mean DD Pain Ratio | 4.70 |
| Current Volume | 1224.6k |
| Average Volume | 1454.2k |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (11.68b TTM) > 0 and > 6% of Revenue (6% = 3.36b TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -1.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.79% (prev 6.27%; Δ -13.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 678.5m <= Net Income 11.68b (YES >=105%, WARN >=100%) |
| Net Debt (20.36b) to EBITDA (17.09b) ratio: 1.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.94b) change vs 12m ago -4.29% (target <= -2.0% for YES) |
| Gross Margin 82.38% (prev 74.92%; Δ 7.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.15% (prev 48.24%; Δ 4.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.60 (EBITDA TTM 17.09b / Interest Expense TTM 836.9m) >= 6 (WARN >= 3) |
Altman Z'' 2.67
| (A) -0.04 = (Total Current Assets 28.20b - Total Current Liabilities 32.00b) / Total Assets 107.29b |
| (B) 0.41 = Retained Earnings (Balance) 43.61b / Total Assets 107.29b |
| (C) 0.12 = EBIT TTM 13.06b / Avg Total Assets 105.41b |
| (D) 0.71 = Book Value of Equity 44.37b / Total Liabilities 62.54b |
| Total Rating: 2.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.56
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 4.30% = 2.15 |
| 3. FCF Margin 20.20% = 5.05 |
| 4. Debt/Equity 0.68 = 2.28 |
| 5. Debt/Ebitda 1.19 = 1.48 |
| 6. ROIC - WACC (= 8.70)% = 10.88 |
| 7. RoE 27.69% = 2.31 |
| 8. Rev. Trend 79.62% = 5.97 |
| 9. EPS Trend 88.76% = 4.44 |
What is the price of NVS shares?
Over the past week, the price has changed by +2.70%, over one month by -2.18%, over three months by +7.30% and over the past year by +24.71%.
Is Novartis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVS is around 142.83 USD . This means that NVS is currently undervalued and has a potential upside of +12.29% (Margin of Safety).
Is NVS a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 2
What are the forecasts/targets for the NVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 130.5 | 2.6% |
| Analysts Target Price | 130.5 | 2.6% |
| ValueRay Target Price | 157.6 | 23.9% |
NVS Fundamental Data Overview November 11, 2025
P/E Trailing = 17.2609
P/E Forward = 14.1844
P/S = 4.306
P/B = 6.0388
P/EG = 1.3644
Beta = 0.439
Revenue TTM = 56.02b USD
EBIT TTM = 13.06b USD
EBITDA TTM = 17.09b USD
Long Term Debt = 21.37b USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.78b USD (from shortTermDebt, last quarter)
Debt = 30.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.36b USD (from netDebt column, last quarter)
Enterprise Value = 263.11b USD (242.74b + Debt 30.12b - CCE 9.75b)
Interest Coverage Ratio = 15.60 (Ebit TTM 13.06b / Interest Expense TTM 836.9m)
FCF Yield = 4.30% (FCF TTM 11.32b / Enterprise Value 263.11b)
FCF Margin = 20.20% (FCF TTM 11.32b / Revenue TTM 56.02b)
Net Margin = 20.85% (Net Income TTM 11.68b / Revenue TTM 56.02b)
Gross Margin = 82.38% ((Revenue TTM 56.02b - Cost of Revenue TTM 9.87b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.61%)
Tobins Q-Ratio = 2.45 (Enterprise Value 263.11b / Total Assets 107.29b)
Interest Expense / Debt = 0.97% (Interest Expense 293.6m / Debt 30.12b)
Taxrate = 12.47% (1.70b / 13.64b)
NOPAT = 11.43b (EBIT 13.06b * (1 - 12.47%))
Current Ratio = 0.88 (Total Current Assets 28.20b / Total Current Liabilities 32.00b)
Debt / Equity = 0.68 (Debt 30.12b / totalStockholderEquity, last quarter 44.33b)
Debt / EBITDA = 1.19 (Net Debt 20.36b / EBITDA 17.09b)
Debt / FCF = 1.80 (Net Debt 20.36b / FCF TTM 11.32b)
Total Stockholder Equity = 42.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.89% (Net Income 11.68b / Total Assets 107.29b)
RoE = 27.69% (Net Income TTM 11.68b / Total Stockholder Equity 42.18b)
RoCE = 20.55% (EBIT 13.06b / Capital Employed (Equity 42.18b + L.T.Debt 21.37b))
RoIC = 16.01% (NOPAT 11.43b / Invested Capital 71.37b)
WACC = 7.31% (E(242.74b)/V(272.86b) * Re(8.11%) + D(30.12b)/V(272.86b) * Rd(0.97%) * (1-Tc(0.12)))
Discount Rate = 8.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 78.85% ; FCFE base≈11.79b ; Y1≈12.45b ; Y5≈14.73b
Fair Price DCF = 132.9 (DCF Value 254.99b / Shares Outstanding 1.92b; 5y FCF grow 6.12% → 3.0% )
EPS Correlation: 88.76 | EPS CAGR: 15.33% | SUE: -0.57 | # QB: 0
Revenue Correlation: 79.62 | Revenue CAGR: 2.51% | SUE: 0.32 | # QB: 0
Additional Sources for NVS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle